CJC-1295 (no dac) 10mg + Ipamorelin 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of CJC-1295 / Ipamorelin Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF-CJCIPA10/10-B241

Key analytical results include:

• Ipamorelin Assay Content: 10.06 mg
• Ipamorelin Identification – Retention Time: 1.000
• CJC-1295 (MOD GRF 1-29) Assay Content: 10.67 mg
• CJC-1295 Identification – Retention Time: 0.989
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

CJC-1295 / Ipamorelin is a dual-peptide research preparation combining two synthetic peptides frequently studied in controlled laboratory environments investigating peptide-mediated endocrine signalling systems.

The formulation combines CJC-1295 (MOD GRF 1-29), a growth hormone releasing hormone analogue, with Ipamorelin, a selective peptide studied in relation to growth hormone secretagogue receptor interaction pathways.

This preparation contains a combined 20 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the preparation for controlled in vitro experimentation.

Because of their defined peptide structures and stable analytical profiles, CJC-1295 and Ipamorelin are widely referenced in experimental models exploring endocrine signalling and peptide-receptor interactions.

Compound Overview

CJC-1295 (MOD GRF 1-29) is a modified analogue of growth hormone releasing hormone originally developed to study hormone signalling pathways and receptor-mediated endocrine regulation.

Ipamorelin is a synthetic pentapeptide investigated for its interaction with growth hormone secretagogue receptors within experimental endocrine signalling models.

Within biochemical research environments, both peptides are frequently examined for their role in receptor-mediated signalling cascades and peptide-hormone regulatory networks.

The combination of these peptides within a single preparation allows researchers to investigate comparative signalling behaviour and peptide interaction dynamics in controlled laboratory systems.

Historical Background and Scientific Context

Interest in synthetic hormone-regulating peptides expanded significantly during the late twentieth century as molecular biology techniques enabled researchers to study endocrine signalling pathways at the receptor level.

Growth hormone releasing hormone analogues such as CJC-1295 were developed as research tools to investigate hormonal regulatory mechanisms and receptor signalling processes.

Similarly, secretagogue peptides such as Ipamorelin were introduced in laboratory research to explore receptor-mediated peptide signalling and endocrine regulatory pathways.

Modern research frequently investigates combinations of peptides in order to study complex signalling interactions within endocrine and cellular regulatory systems.

Mechanistic Focus in Research

Within experimental laboratory environments, CJC-1295 / Ipamorelin blends are studied in relation to peptide-receptor interaction pathways and endocrine signalling mechanisms.

Research investigations commonly explore the peptides in experimental models examining:

• Growth hormone releasing hormone receptor signalling
• Growth hormone secretagogue receptor interaction
• Endocrine signalling pathway dynamics
• Peptide-mediated receptor activation studies
• Intracellular signalling cascade modelling
• Comparative peptide interaction research
• Hormonal regulatory network analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing endocrine signalling and peptide-receptor interaction pathways.

Research Applications

In controlled research environments, CJC-1295 / Ipamorelin blends may be utilised in experimental models designed to explore endocrine signalling systems and peptide-mediated receptor pathways.

Examples of research applications include:

• Endocrine signalling pathway investigation
• Peptide-receptor interaction research
• Hormonal regulatory mechanism studies
• Cell signalling analysis
• Comparative peptide interaction modelling
• Molecular endocrine pathway research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. (Czechia)
Dual-peptide blend of CJC-1295 (no DAC) and Ipamorelin
Validated assay content: 10.67 mg and 10.06 mg respectively
Retention time identification and full COA traceability
Endotoxin levels below 0.001 EU per mg
No detectable microbial growth or heavy metals
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.